MedTrace Logo

Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin

NCT01823679 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-04-12

Study results available
· View outcomes & findings →

Summary

Phase 2 evaluation of capecitabine in patients with advanced or recurrent squamous cell carcinoma of the skin.

Conditions

  • Squamous Cell Carcinoma of the Skin
  • Recurrent Skin Cancer

Interventions

DRUG

Capecitabine

Given orally

Sponsors & Collaborators

Principal Investigators

  • Alexander Colevas · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01823679 on ClinicalTrials.gov